Stay
Up-To-Date
Articles, publications, podcasts, and more to keep you current on our Vanquish Water Vapor Ablation System.
Francis Medical Receives FDA 510(k) Clearance for Use of the Vanquish® Water Vapor System for Prostate Tissue Ablation in Patients with Intermediate Risk Prostate Cancer
MINNEAPOLIS (Dec. 2, 2025) – Francis Medical, Inc.,a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System ...
Press Release: Francis Medical Announces Completion of Enrollment in the VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
February 25, 2025: Francis Medical completes enrollment in the company's VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment...
Press Release: Francis Medical Announces Close of Record $80 Million Series C Equity Financing
January 8, 2025: Francis Medical raises record $80M in Series C to fund its VAPOR 2 study and U.S. launch of Vanquish, its proprietary prostate cancer treatment...
CEO Mike Kujak Interviewed by Medtech Insight
In a revealing interview with Citeline Commercial's Medtech Insight, CEO Mike Kujak discusses how Francis Medical's Vanquish system is set to redefine prostate cancer treatment...
The MedTech Startup Podcast: CEO Mike Kujak
Francis Medical CEO Mike Kujak shares the highs and lows of being the CEO of a medtech startup and provides a window into the journey at Francis Medical...
Minnesota Physician Article: Vanquish Water Vapor Ablation System
Vanquish Water Vapor Ablation System featured in the October 2023 Minnesota Physician Journal...
Follow Us
Federal law (USA) restricts this device to sale by or on the order of a physician.
Refer to the device User Manual for a list of contraindications, warnings, and cautions.
Training: Do not operate the Vanquish System without completing Francis Medical-provided physician training. Untrained operation of the device may lead to improper use. Improper use can result in patient injury or equipment malfunction.